Please login to the form below

Not currently logged in

NewLink Genetics

This page shows the latest NewLink Genetics news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

The Incyte trial failure was swiftly followed by a decision by NewLink Genetics to review the status of its own IDO1 programme, headed by indoximod and NLG802, and the company later

Latest news

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Communicating in a crisis Communicating in a crisis

    November 2014. Merck &Co buys rights to Ebola vaccine from NewLink Genetics .

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    2, 600. NewLink Genetics/Genentech. Collaboration and licence. For development of NLG919 and next generation IDO pathway inhibitors.

  • Pharma deals during October 2014 Pharma deals during October 2014

    But the classic licence deal lives on. Several classic licences were reported this month, notably NewLink Genetics and Genentech; Curetech and Medivation; Forendo and Apricus as well as Lexicon and Ipsen. . ... Leading the pack, NewLink Genetics secured

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...